Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GLYC | US
-0.00
-0.06%
Healthcare
Biotechnology
30/06/2024
18/10/2024
0.16
0.16
0.16
0.15
GlycoMimetics Inc. a clinical-stage biotechnology company focuses on the discovery and development of glycobiology-based therapies for cancers including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan an E-selectin antagonist which is used in combination with chemotherapy to treat AML as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs including GMI-1687 an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists a carbohydrate-binding protein. In addition it is developing GMI-1359 which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics Inc. was incorporated in 2003 and is headquartered in Rockville Maryland.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
48.6%1 month
53.0%3 months
80.2%6 months
148.5%-
-
0.51
0.02
0.02
-0.48
555.40
-
-40.78M
10.21M
10.21M
-
-408.77K
-
-100.00
-104.49
3.06
3.66
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.03
Range1M
0.04
Range3M
0.19
Rel. volume
0.57
Price X volume
61.05K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Common Stock | ADXN | Biotechnology | 10.44 | 11.16M | -1.51% | n/a | 0.25% |
TransCode Therapeutics Inc. Common Stock | RNAZ | Biotechnology | 0.6131 | 11.03M | 2.35% | 0.00 | 17.19% |
Alterity Therapeutics Limited | ATHE | Biotechnology | 1.26 | 11.02M | 5.00% | n/a | 1.15% |
Immuron Limited | IMRN | Biotechnology | 1.91 | 10.88M | -3.05% | n/a | 1.37% |
SNTI | SNTI | Biotechnology | 2.28 | 10.44M | 6.05% | n/a | 80.96% |
Sensei Biotherapeutics Inc | SNSE | Biotechnology | 0.4131 | 10.39M | -2.50% | n/a | 9.67% |
KPRX | KPRX | Biotechnology | 3.47 | 10.31M | 4.83% | 0.21 | 0.25% |
Orgenesis Inc | ORGS | Biotechnology | 2.11 | 10.07M | -34.84% | n/a | -84.02% |
Enzon Pharmaceuticals Inc | ENZN | Biotechnology | 0.1249 | 9.93M | 12.00 | 0.00% | |
BioCardia Inc | BCDA | Biotechnology | 2.69 | 9.60M | 1.51% | n/a | -58.03% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | 19.98% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | 268.43% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.82 | 0 | 1.93% | 9.09 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.48 | 0.53 | Cheaper |
Ent. to Revenue | 555.40 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.51 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 80.15 | 72.80 | Par |
Debt to Equity | 0.02 | -1.23 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 10.21M | 3.66B | Emerging |